Davita Inc vs iShares Core MSCI EAFE ETF — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while iShares Core MSCI EAFE ETF trades at $100.75. The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | IEFA | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $101.09 |
52-Week Low | $103.87 | $84.72 |
Enterprise Value | $24.44B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
IEFA (iShares Core MSCI EAFE ETF) trades at $101.09, up 1.1% with a bullish technical signal from moving averages. The fund provides exposure to developed international markets excluding the US and Canada, with a competitive 0.07% expense ratio and 3.30% dividend yield. Recent news highlights its role in diversification strategies amid S&P 500 concentration concerns.
The outlook remains positive given international diversification benefits and potential Fed rate cut catalysts. Key risks include developed market monetary policy shifts and currency fluctuations. Analyst sentiment favors IEFA for its cost efficiency and income generation, though emerging market alternatives offer different growth profiles.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →